The MiND paper described a planned pharmacologic neuroimaging experiment. It did not report completed evidence that lorazepam restored younger patterns of brain activity in older adults.
The protocol proposed comparing lorazepam with placebo while measuring neural distinctiveness in younger and older adults. The design used a pharmacologic manipulation to investigate an inhibitory-signaling hypothesis about age-related changes.
A protocol specifies how a question will be tested. Its hypotheses and expected patterns remain different from observed outcomes.
The single-blind design and the possibility of recognizable drug effects were relevant interpretive concerns. A change in an imaging measure would also require separate interpretation from a change in useful cognitive performance.
This source supports explaining the rationale, planned controls, and measurements. It cannot support a statement that the proposed effect occurred, that age-related cognitive decline was reversed, or that lorazepam is an established treatment for it. In research testimony, identify a protocol explicitly so a planned comparison is not presented as a completed trial.
Original analysis of the supplied journal article, identified as PMC6460537.